ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Prognostic Value of Gastric Immune Prognostic Index in Gastric Cancer Patients Treated With PD-1/PD-L1 Inhibitors

Chen, Li; Zhao, Ruihu; Sun, Hao; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*华中科技大学; 哈尔滨医科大学
Frontiers in Pharmacology2022-6-20DOI: 10.3389/fphar.2022.833584
4被引13阅读
引用收藏
分享

摘要

Objective: This study aimed to investigate the prognostic value of the gastric immune prognostic index (GIPI) in gastric cancer patients treated with programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors.Methods: This study was conducted to elucidate the role of GIPI using the data from 146 gastric cancer patients treated with PD-1/PD-L1 inhibitors between August 2016 and December 2020 in Harbin Medical University Cancer Hospital. The GIPI calculation was based on dNLR and LDH. Patients were categorized into three groups: 1) GIPI good (LDH <= 250 U/L and dNLR <= 3); 2) GIPI intermediate (LDH >250 U/L and NLR >3); 3) GIPI poor (LDH >250 U/L and dNLR >3). The correlations between GIPI and clinicopathologic characteristics were determined by the Chi-square test or the Fisher's exact test. The Kaplan-Meier analysis and log-rank test were used to calculate and compare progression-free survival (PFS) and overall survival (OS). The univariate and multivariate Cox proportional hazards regression model was used to detect prognostic and predictive factors of PFS and OS.Results: 146 patients treated with PD-1/PD-L1 inhibitors were included in this study, of which, 72.6% were GIPI good, 23.3% were GIPI intermediate, and 4.1% were GIPI poor. The GIPI was associated with the common blood parameters, including neutrophils and lymphocytes. The multivariate analysis showed that platelet, TNM stage, and treatment were the independent prognostic factors for PFS and OS. Patients with GIPI intermediate/poor were associated with shorter PFS (median: 24.63 vs. 32.50 months; p = 0.078) and OS (median: 28.37 months vs. not reached; p = 0.033) than those with GIPI good. GIPI intermediate/poor was correlated with shorter PFS and OS than GIPI good, especially in subgroups of patients with ICI treatment and patients with PD-1/PD-L1 positive status.Conclusions: The GIPI correlated with poor outcomes for PD-1/PD-L1 expression status and may be useful for identifying gastric cancer patients who are unlikely to benefit from treatment.

学科与关键词

关键词
gastric cancergastric immune prognostic indeximmune checkpoint inhibitorsderived neutrophil to lymphocyte ratiolactate dehydrogenase
相关
加载中…
  • Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
    Sun, Hao; Chen, Li; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhao, Ruihu; Xue, Yingwei; Song, Hongjiang*Frontiers in Nutrition, 2022, 9: 1038118.被引 9
  • Controlling Nutritional Status (CONUT) Predicts Survival in Gastric Cancer Patients With Immune Checkpoint Inhibitor (PD-1/PD-L1) Outcomes
    Chen, Li; Sun, Hao; Zhao, Ruihu; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Li, Xingrui*; Song, Hongjiang*Frontiers in Pharmacology, 2022, 13: 836958.被引 16
  • Controlling nutritional status (CONUT) predicts survival in gastric cancer patients with immune checkpoint inhibitor (PD-1/PD-L1) outcomes (vol 13, 836958, 2022)
    Chen, Li; Sun, Hao; Zhao, Ruihu; Huang, Rong; Pan, Hongming; Zuo, Yanjiao; Zhang, Lele; Xue, Yingwei; Song, Hongjiang*; Li, Xingrui*Frontiers in Pharmacology, 2022, 13: 1079635.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-06-20
卷期
第 13 卷
页码
833584
DOI
10.3389/fphar.2022.833584
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
Department of Education of Heilongjiang Province [12541458]; Clinical Research Foundation of the Wu Jieping Medical Foundation [320.6750.13105, 320.6750.18278]

作者

  • C

    Chen, Li (第一作者)

    harbin med univ · huazhong univ sci & technol

  • Z

    Zhao, Ruihu

    harbin med univ

查看全部 10 位作者收起作者
  • S

    Sun, Hao

    harbin med univ

  • H

    Huang, Rong

    harbin med univ

  • P

    Pan, Hongming

    harbin med univ

  • Z

    Zuo, Yanjiao

    harbin med univ

  • Z

    Zhang, Lele

    harbin med univ

  • X

    Xue, Yingwei

    harbin med univ

  • L

    Li, Xingrui (通讯)

    huazhong univ sci & technol

  • S

    Song, Hongjiang (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417